Recent studies indicate that CRC patients with PIK3CA mutations experienced a significant decrease in mortality when treated with aspirin, whereas no survival benefit was observed in cases with wild-type PIK3CA [68]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.